jak inhibitors
- Home
- jak inhibitors
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer industry as it forges ahead with dosing patients in its Phase 2 clinical trial of SNT-5505 in combination with approved drug ruxolitinib. SNT-5505, a pan-LOX inhibitor designed to target myelofibrosis, a bone marrow cancer where
Read MorePublic
Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials
Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis (ASX: PXS) has quickly jumped forward in the commercialisation process having been cleared by the US Food and Drug Administration (FDA) to commence a combination arm of the trial. The clearance of the amended trial
Read MorePublic
Out-the-box thinkers are just what the myelofibrosis treatment market needs
The pharmaceutical industry is an incredibly competitive space with new drug discoveries cropping up all the time, giving hope that we may soon find resolutions to the complicated medical challenges of today. The competitive nature of the space means that whoever is first to market has a clear advantage. Clinical stage pharmaceutical company Pharmaxis (ASX:
Read MorePublic
